Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$47.98 - $54.4 $236,349 - $267,974
-4,926 Reduced 52.81%
4,401 $238,000
Q4 2023

Jan 11, 2024

SELL
$48.48 - $57.85 $334,415 - $399,049
-6,898 Reduced 42.51%
9,327 $478,000
Q3 2023

Oct 11, 2023

SELL
$57.89 - $64.73 $203,657 - $227,720
-3,518 Reduced 17.82%
16,225 $941,000
Q2 2023

Jul 14, 2023

SELL
$63.71 - $70.74 $6,880 - $7,639
-108 Reduced 0.54%
19,743 $1.26 Million
Q1 2023

Apr 12, 2023

BUY
$65.71 - $74.53 $1.3 Million - $1.48 Million
19,851 New
19,851 $1.38 Million
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $277,207 - $328,252
4,048 Added 25.7%
19,799 $1.42 Billion
Q3 2022

Oct 17, 2022

BUY
$0.13 - $76.84 $377 - $222,836
2,900 Added 22.57%
15,751 $1.12 Million
Q2 2022

Jul 12, 2022

BUY
$72.62 - $79.98 $53,012 - $58,385
730 Added 6.02%
12,851 $990,000
Q4 2021

Jan 21, 2022

BUY
$53.63 - $62.52 $86,022 - $100,282
1,604 Added 15.25%
12,121 $750,000
Q3 2021

Oct 25, 2021

BUY
$59.17 - $69.31 $19,821 - $23,218
335 Added 3.29%
10,517 $622,000
Q2 2021

Jul 21, 2021

SELL
$61.91 - $67.42 $14,301 - $15,574
-231 Reduced 2.22%
10,182 $680,000
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $63,137 - $71,011
1,064 Added 11.38%
10,413 $657,000
Q3 2020

Nov 10, 2020

SELL
$57.43 - $63.64 $40,201 - $44,548
-700 Reduced 6.97%
9,349 $563,000
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $86,451 - $101,069
-1,577 Reduced 13.56%
10,049 $590,000
Q1 2020

May 12, 2020

SELL
$46.4 - $67.43 $55,401 - $80,511
-1,194 Reduced 9.31%
11,626 $648,000
Q4 2019

Jan 30, 2020

BUY
$49.21 - $64.19 $630,872 - $822,915
12,820 New
12,820 $856,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cfm Wealth Partners LLC Portfolio

Follow Cfm Wealth Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cfm Wealth Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cfm Wealth Partners LLC with notifications on news.